Phaseline

Targets › CMAH

CMAH (Inactive cytidine monophosphate-N-acetylneuraminic acid hydroxylase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Oct 2028.

Sialic acids are components of carbohydrate chains of glycoconjugates and are involved in cell-cell recognition and cell-pathogen interactions. That protein has no CMP-N-acetylneuraminate monooxygenase activity and is not able to convert CMP-N-acetylneuraminic acid (CMP-Neu5Ac) into its hydroxylated derivative CMP-N-glycolylneuraminic acid (CMP-Neu5Gc), a sialic acid abundantly expressed at the surface of many cells…. (UniProt, Q9Y471)

Open in Phaseline: the race on CMAH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
United Therapeutics10 GE Xenokidney
Porcine-derived kidney with intentional genomic alterations (knockout of GGTA1, CMAH, BHMT
GGTA1, CMAH, BHMT, PERVPhase 1ESRD (End-Stage Renal Disease)Oct 2028

Conditions

ESRD (End-Stage Renal Disease) (1)

Modalities

protein or peptide (1)

Companies

United Therapeutics (1)

Related targets

GGTA1 (1) BHMT (1) PERV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.